Tenaya Therapeutics Inc Stock News

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual G...

Tenaya Therapeutics (TNYA -2.99%), a clinical-stage biotechnology company focused on genetic therapies for heart disease, released second-quarter results on August 6, 2025. Tenaya posted a net loss per share of $(0.14) (GAAP) for Q2 2025, narrower than the $(0.19) loss analysts had predicted.

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™ -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts

Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of  TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from  Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three ne...

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease

RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene

TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201;  RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report ...